PKS Advisory Services LLC Takes Position in Stryker Co. (NYSE:SYK)

PKS Advisory Services LLC acquired a new stake in Stryker Co. (NYSE:SYK - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,511 shares of the medical technology company's stock, valued at approximately $904,000.

Several other hedge funds have also recently made changes to their positions in SYK. Chicago Capital LLC lifted its holdings in Stryker by 3.1% during the fourth quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company's stock worth $70,228,000 after acquiring an additional 5,841 shares during the period. Zhang Financial LLC boosted its position in Stryker by 55.0% during the 4th quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company's stock valued at $41,366,000 after acquiring an additional 40,784 shares in the last quarter. Appleton Partners Inc. MA boosted its stake in Stryker by 5.0% in the 4th quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company's stock worth $10,521,000 after purchasing an additional 1,400 shares in the last quarter. Metis Global Partners LLC boosted its stake in shares of Stryker by 10.2% in the 4th quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company's stock worth $6,064,000 after buying an additional 1,561 shares during the last quarter. Finally, US Bancorp DE lifted its position in Stryker by 0.5% during the fourth quarter. US Bancorp DE now owns 182,825 shares of the medical technology company's stock valued at $65,829,000 after purchasing an additional 976 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Remove Ads

Stryker Trading Down 0.9 %

NYSE SYK traded down $3.16 during mid-day trading on Friday, reaching $364.38. 1,274,307 shares of the stock were exchanged, compared to its average volume of 1,289,456. The business's fifty day simple moving average is $384.08 and its 200 day simple moving average is $374.32. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The stock has a market capitalization of $139.08 billion, a PE ratio of 46.96, a PEG ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the company posted $3.46 EPS. On average, research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.92%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's dividend payout ratio (DPR) is currently 43.30%.

Insider Activity at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the business's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. The Goldman Sachs Group set a $422.00 price objective on shares of Stryker in a research report on Tuesday, March 4th. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a report on Tuesday, February 18th. Morgan Stanley upgraded Stryker from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $370.00 to $445.00 in a report on Monday, December 2nd. Stifel Nicolaus increased their price objective on shares of Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a research report on Wednesday, January 29th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $442.00 price objective on shares of Stryker in a research report on Friday, March 21st. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $421.90.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.